Description
Sumatriptan is a tryptamine agonist at 5-HT1B/1D receptors that is clinically used to treat migraines. Sumatriptan exhibits vasoconstrictive and gastrointestinal motility modulating activities. The anti-migraine activity of sumatriptan is likely due to its vasoconstrictive activity and ability to decrease the release of substance P and CGRP. Sumatriptan also increases gastric relaxation and delays gastric emptying. Additionally, this compound inhibits 5-HT- and capsaicin-induced signaling of transient receptor potential vanilloid (TRPV1) channels and release of CGRP in vitro and in vivo.
References
Blumenfeld A, Gennings C, Cady R. Pharmacological synergy: the next frontier on therapeutic advancement for migraine. Headache. 2012 Apr;52(4):636-47. PMID: 22221151.
Loyd DR, Weiss G, Henry MA, et al. Serotonin increases the functional activity of capsaicin-sensitive rat trigeminal nociceptors via peripheral serotonin receptors. Pain. 2011 Oct;152(10):2267-76. PMID: 21737202.
Muñoz-Islas E, Lozano-Cuenca J, González-Hernández A, et al. Spinal sumatriptan inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors. Eur J Pharmacol. 2009 Aug 1;615(1-3):133-8. PMID: 19460365.
Moro E, Crema F, De Ponti F, et al. Triptans and gastric accommodation: pharmacological and therapeutic aspects. Dig Liver Dis. 2004 Jan;36(1):85-92. PMID: 14971822.
